Patents Assigned to The United States of America as represented by the Secretary, Department of Health and Human Services
-
Patent number: 11666663Abstract: Disclosed are nanostructures comprising a ribonucleic acid (RNA) scaffold comprising a hexameric tetrahedral core. The tetrahedral core may comprise four hexameric RNA nanorings linked together. Related pharmaceutical compositions, methods of modulating the expression of a target gene in a mammal, methods of treating or preventing a disease in a mammal, and methods of producing a hexameric tetrahedral RNA nanostructure are also disclosed.Type: GrantFiled: May 8, 2019Date of Patent: June 6, 2023Assignees: The United States of America,as represented by the Secretary, Department of Health and Human Services, The Regents of the University of CaliforniaInventors: Bruce A. Shapiro, Paul J. Zakrevsky, Luc Jaeger
-
Patent number: 11667692Abstract: Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented in the context of an HLA-Cw*0802 molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.Type: GrantFiled: January 10, 2020Date of Patent: June 6, 2023Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Eric Tran, Yong-Chen Lu, Steven A. Rosenberg
-
Patent number: 11661439Abstract: This disclosure provides novel anionic amphiphilic ?-hairpin peptides that self-assemble under appropriate conditions to form a reversible gel-sol hydrogel that can be used, for example, to readily deliver protein therapeutics and cells by injection to a target location in a subject.Type: GrantFiled: December 17, 2017Date of Patent: May 30, 2023Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Joel Schneider, Scott Walsh, Stephen Miller, Yuji Yamada, Scott Durum, Caroline Andrews, Wenqing Li, Julie Hixon, Steven Tau
-
Publication number: 20230159953Abstract: Closed-ended, linear, duplex (CELiD) DNA molecules, recombinant AAV (rAAV), particles comprising CELiD DNA, methods of making such molecules and particles, and therapeutic applications of such particles.Type: ApplicationFiled: January 9, 2023Publication date: May 25, 2023Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Lina Li, Robert Kotin
-
Publication number: 20230158075Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes a method of conditioning a patient prior to a T cell therapy, wherein the conditioning involves administering a combination of cyclophosphamide and fludarabine.Type: ApplicationFiled: September 27, 2022Publication date: May 25, 2023Applicants: Kite Pharma Inc., United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Adrian BOT, Jeffrey WIEZOREK, William GO, Rajul JAIN, James N. KOCHENDERFER, Steven A. ROSENBERG
-
Publication number: 20230159614Abstract: Disclosed are isolated or purified T cell receptors (TCRs), wherein the TCRs have antigenic specificity for a mutated RAS amino acid sequence presented by a human leukocyte antigen (HLA) Class II molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.Type: ApplicationFiled: February 26, 2021Publication date: May 25, 2023Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Noam Levin, Rami Yoseph, Biman C. Paria, Steven A. Rosenberg
-
Patent number: 11655469Abstract: Disclosed herein are methods of treating a tumor in a subject, including administering to the subject one or more miRNA nucleic acids or variants (such as mimics or mimetics) thereof with altered expression in the tumor. Also disclosed herein are compositions including one or more miRNA nucleic acids. In some examples, the miRNA nucleic acids are modified miRNAs, for example, and miRNA nucleic acid including one or more modified nucleotides and/or a 5?-end and/or 3?-end modification. In particular examples, the modified miRNA nucleic acid is an miR-30a nucleic acid. Further disclosed herein are methods of diagnosing a subject as having a tumor with altered expression of one or more miRNA nucleic acids. In some embodiments, the methods include detecting expression of one or more miRNAs in a sample from the subject and comparing the expression in the sample from the subject to a control.Type: GrantFiled: March 7, 2017Date of Patent: May 23, 2023Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, miRenlo, Inc.Inventors: Anthony D. Saleh, Carter Van Waes, Zhong Chen, Hui Cheng
-
Publication number: 20230154215Abstract: A method is provided for non-invasively predicting characteristics of one or more cells and cell derivatives. The method includes training a machine learning model using at least one of a plurality of training cell images representing a plurality of cells and data identifying characteristics for the plurality of cells. The method further includes receiving at least one test cell image representing at least one test cell being evaluated, the at least one test cell image being acquired noninvasively and based on absorbance as an absolute measure of light, and providing the at least one test cell image to the trained machine learning model. Using machine learning based on the trained machine learning model, characteristics of the at least one test cell are predicted. The method further includes generating, by the trained machine learning model, release criteria for clinical preparations of cells based on the predicted characteristics of the at least one test cell.Type: ApplicationFiled: November 9, 2022Publication date: May 18, 2023Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Kapil Bharti, Nathan A. Hotaling, Nicholas J. Schaub, Carl G. Simon
-
Patent number: 11649218Abstract: Disclosed herein are embodiments of a compound that inhibits c-Abl tyrosine kinase (also referred to herein as “c-Abl”). The compound embodiments described herein are novel c-Abl inhibitors that can bind to c-Abl at an allosteric site and inhibit its activity in various pathways. The compound embodiments also are capable of crossing the blood brain barrier and therefore are useful in inhibiting c-Abl activity as it affects pathways and/or proteins in the brain. The compound embodiments described herein are effective therapeutic agents for treating diseases involving c-Abl, such as cancers, motor neuron diseases, and neurodegenerative diseases. Also disclosed herein are embodiments of methods for making and using the c-Abl inhibitory compound embodiments.Type: GrantFiled: March 8, 2019Date of Patent: May 16, 2023Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Pontificia Universidad Catolica de ChileInventors: Juan J. Marugan, Marc Ferrer, Noel T. Southall, Andres E. Dulcey, Xin Hu, Christopher R. Dextras, Daniel C. Talley, Alejandra Alvarez, Silvana Zanlungo, Rommy M. Von Bernhardi
-
Patent number: 11646099Abstract: In embodiments of the invention, the invention provides a method for distinguishing between lymphoma types based on gene expression measurements. In embodiments, the invention distinguishes between PMBCL and DLBCL based on gene expression signatures, and can further distinguish between DLBCL subtypes. In embodiments of the invention, the distinctions are used in methods of treatment.Type: GrantFiled: December 13, 2019Date of Patent: May 9, 2023Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, British Columbia Cancer Agency, Mayo Foundation for Medical Education and Research, Julius-Maximilians-University of Würzburg, Boatd of Regents of the University of Nebraska, Oslo University Hospital HF, Hospital Clinic de Barcelona, Universitat de Barceloa, Institut D'Investigacions Biomédiques Pi I Sunyer (IDIBAPS), Robert Bosch Gesellschaft feuer medizinische Forshung mbH, Oregon Health & Science University, City of Hope, The Cleveland Clinic FoundationInventors: Louis M. Staudt, Christian Steidl, Anja Mottok, George W. Wright, David William Scott, Lisa M. Rimsza, Andreas Rosenwald, Randy Gascoyne, Timothy Greiner, Dennis Weisenburger, Erlend B. Smeland, Jan Delabie, Elias Campo Guerri, German Ott, Rita Braziel, Elaine S. Jaffe, Kai Fu, Wing C. Chan, Joo Song, James R. Cook
-
Patent number: 11642375Abstract: Genetically modified compositions, such as non-viral vectors and T cells, for treating cancer are disclosed. Also disclosed are the methods of making and using the genetically modified compositions in treating cancer.Type: GrantFiled: November 6, 2018Date of Patent: May 9, 2023Assignees: INTIMA BIOSCIENCE, INC., REGENTS OF THE UNIVERSITY OF MINNESOTA, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: Branden Moriarity, Beau Webber, Modassir Choudhry, Steven A. Rosenberg, Douglas C. Palmer, Nicholas P. Restifo
-
Patent number: 11642374Abstract: Genetically modified compositions, such as non-viral vectors and T cells, for treating cancer are disclosed. Also disclosed are the methods of making and using the genetically modified compositions in treating cancer.Type: GrantFiled: November 6, 2018Date of Patent: May 9, 2023Assignees: INTIMA BIOSCIENCE, INC., REGENTS OF THE UNIVERSITY OF MINNESOTA, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: Branden Moriarity, Beau Webber, Modassir Choudhry, Steven A. Rosenberg, Douglas C. Palmer, Nicholas P. Restifo
-
Publication number: 20230135524Abstract: Disclosed is a compound of formula (I) in which R1, R2, R3, X1, X2, X2?, X3, X4, ring A, m, n, and o are as described herein. The compound of formula (I) is useful for treating a disorder associated with androgen receptor malfunction, such as a hyperproliferative disorder, in a subject in need thereof.Type: ApplicationFiled: January 20, 2021Publication date: May 4, 2023Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services, Georgia Tech Research CorporationInventors: Berkley E. Gryder, Adegboyega K. Oyelere, Subhasish Tapadar, Jonathan D. Strope, William Douglas Figg, Sr.
-
Publication number: 20230139588Abstract: Disclosed are methods of preparing an isolated population of human papillomavirus (HPV)-specific T cells comprise dividing an HPV-positive tumor sample into multiple fragments; separately culturing the multiple fragments; obtaining T cells from the cultured multiple fragments; testing the T cells for specific autologous HPV-positive tumor recognition; selecting the T cells that exhibit specific autologous HPV-positive tumor recognition; and expanding the number of selected T cells to produce a population of HPV-specific T cells for adoptive cell therapy. Related methods of treating or preventing cancer using the T cells are also disclosed.Type: ApplicationFiled: June 13, 2022Publication date: May 4, 2023Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Christian S. Hinrichs, Steven A. Rosenberg
-
Publication number: 20230138309Abstract: Provided are methods of preparing an enriched population of T cells having antigenic specificity for a target antigen. The method may comprise isolating T cells from a tumor sample of a patient; selecting the isolated T cells which have a gene expression profile; and separating the selected T cells from the unselected cells. The separated selected T cells provide an enriched population of T cells having antigenic specificity for the target antigen. Methods of isolating a T cell receptor (TCR), preparing a population of cells that express a TCR, isolated TCRs, isolated populations of cells, pharmaceutical compositions, and methods of treating or preventing a condition in a mammal are also provided.Type: ApplicationFiled: March 19, 2021Publication date: May 4, 2023Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Sri Krishna, Frank J. Lowery, III, Ken-ichi Hanada, James C. Yang, Steven A. Rosenberg, Paul F. Robbins, Rami Yoseph
-
Patent number: 11639930Abstract: Identification of immunodominant Babesia microti antigens using genome-wide immunoscreening is described. Candidate antigens were screened against sera from patients with clinical babesiosis. Also described are diagnostic assays with high sensitivity and specificity for detecting B. microti-specific antibodies in patient samples using the identified immunodominant antigens.Type: GrantFiled: November 1, 2018Date of Patent: May 2, 2023Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Yale UniversityInventors: Sanjai Kumar, Nitin Verma, Ankit Puri, Peter J. Krause
-
Patent number: 11633471Abstract: An immunogen generally includes a virus-like particle and an antigen linked to the virus-like particle. The antigen includes an antigenic portion of a polypeptide, wherein the polypeptide inhibits lipoprotein lipase (LPL) activity by binding to LPL. In some embodiments, the polypeptide is at least a portion of angiopoietin-like 3 (ANGPTL3). In other embodiments, the polypeptide is at least a portion of angiopoietin-like 4 (ANGPTL4). In other embodiments, the polypeptide at least a portion of angiopoietin-like 8 (ANGPTL8). In some embodiments, the virus-like particle is a Qbeta immunogenic carrier. In some of these embodiments, the antigen is linked to the virus-like particle through a Gly-Gly-Gly-Cys linker at the C-terminal of the antigen.Type: GrantFiled: March 6, 2019Date of Patent: April 25, 2023Assignees: UNM Rainforest Innovations, The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Bryce Chackerian, Alan Remaley, Marcelo Amar, Alexandra Fowler
-
Patent number: 11634404Abstract: The disclosure of a compound of Formula (I) or a pharmaceutically acceptable salt thereof (I) The variables W, R1, R2, R3, and R4 are defined in the disclosure. The disclosure provides a compound or salt of Formula (I) together with a pharmaceutically acceptable carrier. The disclosure also provides methods of treating a patient for Parkinson's disease and related syndromes, dyskinesia, especially dyskinesias secondary to treating Parkinson's disease with L-DOPA, neurodegenerative disorders such as Alzheimer's disease and dementia, Huntington's disease, restless legs syndrome, bipolar disorder and depression, schizophrenia, cognitive dysfunction, or substance use disorders, the methods comprising administering a compound of Formula I or salt thereof to the patient. The disclosure provides combination methods of treatment in which the compound of Formula (I) is administered to the patient together with one or more additional active agents.Type: GrantFiled: April 14, 2017Date of Patent: April 25, 2023Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE UNIVERSITY OF KANSAS, THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILLInventors: David R. Sibley, Amy Elizabeth Moritz, R. Benjamin Free, Joseph P. Steiner, Noel Terrence Southall, Marc Ferrer, Xin Hu, Warren S. Weiner, Jeffrey Aubé, Kevin Frankowski
-
Patent number: 11634459Abstract: Chimeric flaviviruses engineered to contain a reporter gene and chimeric nucleic acid molecules encoding the chimeric flaviviruses are described. The chimeric flaviviruses further include genomic non-coding regions, non-structural proteins, and at least a portion of a capsid (C) protein from West Nile virus (WNV), and premembrane (prM) and envelope (E) proteins from dengue virus (DENV). Diagnostic assays that utilize chimeric West Nile/dengue viruses are further described.Type: GrantFiled: August 17, 2018Date of Patent: April 25, 2023Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventor: Claire Y. Kinney
-
Patent number: 11623220Abstract: A container comprising: a first panel; a second panel opposing the first panel; a first side; a second side opposing the first side; a third side; a fourth side opposing the third side; wherein each of the sides joins the first panel and the second panel; a chamber defined by the four sides, the first panel, and the second panel, wherein the chamber is configured to receive a biological specimen; a port defined in the first side; a plug inserted into the port; an opening defined in the second side; and a closure element coupled to the opening, wherein the chamber is leak proof.Type: GrantFiled: April 26, 2018Date of Patent: April 11, 2023Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Stephen M. Hewitt, Robert A. Star, Jeffrey C. Hanson, Hiroshi Kojima, Russell Bandle, Armando Filie